Advancing Beyond Existing CDK4/6 to Overcome Resistance

Opportunity to Address Resistance-Driven Gaps in Metastatic Breast Cancer and Other Hard-to-Treat Tumors

A small molecule kinase inhibitor (including PLK-1).

We are actively seeking development and commercialization partners for our legacy clinical oncology programs, rigosertib and narazaciclib.

For more information or to discuss potential partnering opportunities, please contact idukes@trawspharma.com